このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Preoperative CA 19-9 and the Pattern and Timing of Recurrence After Pancreatoduodenectomy (Whipple Operation) for Pancreatic Cancer (CA199-PATTERN)

2026年11月13日 更新者:Saleh Khairy Saleh MD、Minia University

Correlation of Preoperative Serum CA 19-9 With the Pattern and Timing of Recurrence After Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Retrospective Cohort Study

Surgery to remove the head of the pancreas (pancreatoduodenectomy, also called the Whipple operation), usually followed by chemotherapy, is the only treatment that offers long-term survival for cancer in the head of the pancreas (pancreatic ductal adenocarcinoma). Even so, the cancer comes back (recurs) in most patients. Where it comes back first (around the operation site, in the liver, in the lining of the abdomen, in the lungs or elsewhere) and how soon it comes back both affect survival, the choice of further treatment and how patients should be followed up.

CA 19-9 is a blood test measured routinely before this operation. A high level is known to be linked with shorter survival, but whether it also predicts where and when the cancer will recur is uncertain and, to the investigator's knowledge, has not been studied in patients treated in Egypt. Jaundice, which is common in these patients, can raise CA 19-9 falsely, so this study uses only CA 19-9 values measured when the blood bilirubin level was close to normal (2 mg/dL or less).

This is a retrospective study of existing medical records. It includes adults who had a Whipple operation for this cancer at the Hepatopancreatobiliary and Surgical Oncology Unit, Liver and GIT Hospital, Minia University, Egypt, between January 2017 and December 2024, with follow-up information from Minia Oncology Centre. No patient will receive any test or treatment for the study, and no care will be changed. Patients will be compared according to their preoperative CA 19-9 level (37 U/mL or less versus more than 37 U/mL).

The two main questions are whether the preoperative CA 19-9 level is linked to (1) the site of the first recurrence and (2) the time from surgery to recurrence. A recurrence will count only when confirmed by scans or biopsy, never by a rising CA 19-9 alone, and it will be classified by independent doctors who do not know the patients' CA 19-9 results. Other questions include recurrence within 6 and 12 months of surgery, survival, and whether CA 19-9 adds useful information to the routine findings available before surgery.

The investigator expects that patients with a high CA 19-9 will more often recur first in the liver or the lining of the abdomen and will recur sooner, whereas patients with a normal level will recur later and more often only near the operation site. The findings may help tailor follow-up after surgery, identify patients who might benefit from chemotherapy before surgery, and identify patients whose cancer is likely to come back only at the operation site, who might be considered for further local treatment.

調査の概要

詳細な説明

BACKGROUND AND RATIONALE

Pancreatoduodenectomy followed by adjuvant systemic therapy is the only treatment sequence associated with long-term survival for pancreatic ductal adenocarcinoma (PDAC) of the pancreatic head, yet most patients recur even after a margin-negative resection and completed adjuvant chemotherapy. The site of first failure and its timing carry separate prognostic information. Hepatic and peritoneal failure carry a worse outlook than isolated local recurrence, which may occasionally be amenable to re-resection or stereotactic radiotherapy, and 12 months of recurrence-free survival separates early from late recurrence with markedly different survival after recurrence. Nodal status alters the timing of recurrence without materially altering its anatomical distribution, so this study treats pattern and timing as two separate primary questions.

Serum carbohydrate antigen 19-9 (CA 19-9; sialyl Lewis a) is the only serum biomarker in routine clinical use for this disease, and an elevated preoperative value is consistently associated with shorter overall and recurrence-free survival. Three properties constrain its interpretation: approximately 5-10% of people are Lewis-negative non-secretors who cannot synthesise the antigen; biliary obstruction raises CA 19-9 independently of tumour burden; and no threshold above the conventional upper limit of normal (37 U/mL) has been universally adopted.

Three gaps motivate the study. First, most evidence linking preoperative CA 19-9 to outcome uses composite endpoints (overall or recurrence-free survival) that collapse anatomically and biologically distinct failure events; whether the marker predicts where a patient will fail has been examined in few series and, to the investigator's knowledge, never in an Egyptian or North African population. Second, studies of recurrence pattern have generally treated death without recurrence as non-informative censoring, which misstates absolute risk; a competing-risk formulation is preferable. Third, confounding by obstructive jaundice and biliary drainage is rarely handled by an explicit, pre-specified rule for measuring the exposure. Egyptian practice also differs from the settings that dominate this literature: upfront surgery predominates for resectable disease, obstructive jaundice at presentation is common, preoperative biliary drainage is frequently required, and access to multi-agent adjuvant chemotherapy is variable. Because serum tumour markers are insufficient as a stand-alone criterion for recurrence, and because CA 19-9 is also the exposure, admitting a rising marker as evidence of recurrence would make any finding circular; recurrence therefore requires radiological or histological confirmation throughout.

OBJECTIVES

  • Primary: to determine whether the index preoperative serum CA 19-9 concentration is associated with (1) the anatomical pattern of first recurrence after pancreatoduodenectomy for PDAC and (2) the time from operation to first recurrence, with death without recurrence treated as a competing event.
  • Secondary: association with early (≤12 months) and very early (≤6 months) recurrence; site-specific cumulative incidence of first recurrence at 6, 12, 24 and 36 months, overall and by CA 19-9 stratum; association with recurrence-free, overall and post-recurrence survival; the prognostic contribution of CA 19-9 relative to established pathological predictors and its incremental discrimination over routinely available preoperative variables; and description of perioperative outcomes, adjuvant treatment delivery and surveillance completeness.
  • Exploratory: a data-driven CA 19-9 threshold separating early from late recurrence (not to be presented as a validated cut-off); characteristics and outcomes of patients with CA 19-9 below 2 U/mL (presumed Lewis-negative non-secretors); and whether the CA 19-9 to total bilirubin ratio retains prognostic information in patients for whom no bilirubin-qualified value was obtainable.

HYPOTHESES

Among patients who recur, an elevated index CA 19-9 (>37 U/mL) is associated with a higher relative frequency of distant-only first recurrence, particularly hepatic and peritoneal, and a lower relative frequency of local/locoregional-only first recurrence. An elevated index CA 19-9 is associated with a higher subdistribution hazard of recurrence, with an anticipated hazard ratio of approximately 1.8 relative to a normal value. Null hypotheses: the distribution of first-recurrence patterns and the subdistribution hazard of recurrence do not differ across CA 19-9 strata. Hypotheses are directional, but all tests are two-sided at alpha 0.05.

DESIGN, SETTING AND PERIOD

Single-institution, two-site, retrospective observational cohort study with a competing-risk outcome framework. Operative, anaesthetic, laboratory, radiology and synoptic pathology records come from the Hepatopancreatobiliary and Surgical Oncology Unit and the Department of Pathology, Liver and GIT Hospital, Faculty of Medicine, Minia University; adjuvant treatment, surveillance imaging, tumour-marker trends, recurrence documentation and vital status come from Minia Oncology Centre. Operations performed from 1 January 2017 (establishment of the dedicated hepatopancreatobiliary service, from which synoptic pathology and structured operative records are consistently available) to 31 December 2024 are eligible. Follow-up is censored on 31 August 2026, giving every patient at least 20 months of potential observation. Cumulative incidence is reported to 36 months, and beyond 36 months only where at least 15 patients remain at risk. No aspect of clinical care is altered, and no investigation, sample or patient contact is undertaken for the study other than a single vital-status enquiry where approved. The study follows the STROBE statement for cohort studies. The statistical analysis plan (protocol Section 10) is fixed before database lock; any later change will be dated, documented and reported as a post-hoc amendment.

STANDARD OF CARE DURING THE ACCRUAL WINDOW (CONTEXT ONLY; NOT ALTERED BY THE STUDY)

Pancreatic-protocol contrast-enhanced CT, with MRI/MRCP where the CT is equivocal and endoscopic ultrasound with tissue sampling where a diagnosis is required before treatment; CA 19-9 and CEA at diagnosis and, in jaundiced patients, after biliary decompression; preoperative biliary drainage (endoscopic stenting by default) for cholangitis, severe or symptomatic jaundice, anticipated delay to surgery or nutritional optimisation; review at the joint hepatopancreatobiliary and oncology meeting; pancreatoduodenectomy with standard ISGPS lymphadenectomy, with mesopancreatic excision and an artery-first approach where indicated and venous resection where tumour contact precludes a clear plane; axial slicing with multicolour margin inking and synoptic reporting against the AJCC eighth edition dataset, applying the 1 mm rule; referral for adjuvant chemotherapy within 8 to 12 weeks (gemcitabine monotherapy, gemcitabine with capecitabine, or modified FOLFIRINOX in selected fit patients); and surveillance by clinical review, CA 19-9 and contrast-enhanced CT of the chest, abdomen and pelvis every 3 months for 2 years, then every 6 months to 5 years, with additional imaging for symptoms or a rising marker.

EXPOSURE: INDEX PREOPERATIVE CA 19-9

The index value is the last serum CA 19-9 measured within the 30 days preceding operation at a contemporaneous total bilirubin ≤2 mg/dL (≤34 µmol/L), contemporaneous meaning drawn within 72 hours of the CA 19-9 sample. In patients who underwent preoperative biliary drainage it is the post-drainage value satisfying that criterion; pre-drainage values are recorded separately and never used as the exposure. Where several values qualify, the one closest to operation is used; where none qualifies, the patient enters the secondary cohort and is analysed only in sensitivity analysis S2. Assays are electrochemiluminescence immunoassays; the platform, reference interval and reporting limits in force in each calendar year are tabulated, and any change of platform is entered as a covariate in a sensitivity analysis. Values beyond the limits of quantification are assigned that limit, their number is reported, and a multiple-imputation sensitivity analysis is pre-specified. The exposure is analysed in four pre-specified forms:

  • Ordinal: non-secretor <2; normal 2-37; moderately elevated >37-200; markedly elevated >200 U/mL. Used for descriptive stratification, cumulative incidence functions, Gray's test and pattern tables, with a test for trend across the three producing levels.
  • Binary: >37 versus ≤37 U/mL, with non-secretors in the ≤37 stratum (sensitivity analysis S1 excludes them). Primary statistical contrast for both primary outcomes.
  • Continuous: log2(CA 19-9 + 1), giving the change in hazard per doubling; non-linearity assessed by a restricted cubic spline with knots at the 10th, 50th and 90th centiles.
  • Data-driven threshold (exploratory only): maximally selected rank statistics with the Hothorn-Lausen exact correction, labelled as requiring external validation.

OUTCOME DEFINITIONS

Pattern of first recurrence (mutually exclusive categories):

  • Local/locoregional only: new or progressively enlarging soft tissue in the pancreatic remnant or any anastomosis (pancreaticojejunostomy, hepaticojejunostomy, gastro- or duodenojejunostomy), the pancreatic bed and uncinate groove, perivascular soft tissue of the superior mesenteric artery or coeliac axis, the portal vein/superior mesenteric vein groove, or regional lymph node stations 8, 12, 13, 14 or 17.
  • Liver only: one or more new hepatic lesions with imaging characteristics of metastasis, or proven hepatic metastasis, without disease elsewhere.
  • Peritoneal only: peritoneal or omental nodularity, omental caking, or new ascites with positive cytology or unequivocal accompanying peritoneal nodules, without disease elsewhere; new ascites alone does not qualify.
  • Lung or other distant only: new pulmonary nodules consistent with metastasis, or metastasis at any other distant site (bone, adrenal, distant soft tissue, or non-regional nodes including para-aortic station 16), without disease elsewhere. Station 16 recurrence is deliberately classified as distant nodal, consistent with the AJCC eighth edition.
  • Multiple synchronous sites: disease in two or more categories on the same study or on studies within 30 days of the first evidence of recurrence.

Time to recurrence: months from operation to the first imaging study or biopsy demonstrating recurrence; where recurrence is established by comparison across two studies, the date of the later, confirmatory study. Competing event: death from any cause without documented recurrence. Censoring: alive and recurrence-free at last documented contact or at the follow-up cut-off, whichever is earlier. Early, very early and late recurrence: at or before 12 months, at or before 6 months, and after 12 months, respectively.

RECURRENCE ASCERTAINMENT AND BLINDED ADJUDICATION

Every recurrence requires radiological or histological confirmation. Acceptable evidence is: biopsy or cytology showing adenocarcinoma consistent with the resected primary (the procedure date is the recurrence date); an unequivocal new distant lesion on CECT or MRI, new or progressive locoregional soft tissue ≥10 mm, or a new regional nodal mass ≥10 mm in short axis; a previously indeterminate lesion that has unequivocally enlarged on a study performed at least 6 weeks later (the confirmatory study date is the recurrence date); or focal FDG avidity on PET/CT at a compatible site with a structural correlate on CT or MRI. Not acceptable alone: a rising serum CA 19-9, new or worsening symptoms, clinical suspicion, new ascites without corroboration, or postoperative inflammatory change at the operative bed on early imaging. Patients with biochemical progression but no confirmed recurrence are censored at their last recurrence-free imaging study and counted in a pre-specified sensitivity analysis.

Two clinicians independent of the study (a consultant radiologist and a consultant hepatopancreatobiliary surgeon) independently review all surveillance imaging reports, and the images where equivocal, in packets from which every CA 19-9 value has been removed, recording the fact, date and pattern of recurrence. Disagreement on the fact, on the date by more than 30 days, or on the pattern is resolved by a third independent clinician (a consultant medical oncologist) whose decision is final. Agreement on pattern is reported by Cohen's kappa together with the number of cases requiring adjudication. Whether recurrence was first detected on symptom-triggered or scheduled imaging is recorded.

COVARIATES

Collected in six domains, with permitted values and source documents defined in the case report form and data dictionary: demographic and baseline (age, sex, body mass index, ASA class, ECOG performance status, Charlson age-comorbidity index, new-onset versus longstanding diabetes, smoking); presentation (jaundice, peak bilirubin, biliary drainage modality and interval, cholangitis, albumin, C-reactive protein, haemoglobin, neutrophil and platelet counts with derived ratios, CEA); imaging and staging (CT tumour diameter, NCCN resectability category, radiological nodal status); operative (approach, procedure type, extent of lymphadenectomy, venous or arterial resection, pancreatic texture and duct diameter, operative time, blood loss, transfusion, coded surgeon); pathology (tumour size, grade, pT and pN, nodes examined and involved with lymph node ratio, lymphovascular and perineural invasion, margin status with each margin recorded individually, extrapancreatic extension, background PanIN or IPMN); and postoperative and follow-up (complications graded by Clavien-Dindo, the comprehensive complication index and ISGPS/ISGLS definitions, length of stay, adjuvant therapy, surveillance imaging dates and findings, surveillance CA 19-9 values used descriptively only, recurrence details and vital status). Staging follows the AJCC eighth edition, margin assessment the Leeds Pathology Protocol, and lesion measurement RECIST version 1.1.

DATA SOURCES, EXTRACTION AND QUALITY CONTROL

Data are drawn from the operative logbook and theatre register, hospital electronic and paper records, the clinical pathology laboratory information system (including assay platform and reference intervals), the radiology information system and picture archive, the Department of Pathology archive (blocks and slides available for re-review where a synoptic field is missing or internally inconsistent) and the Minia Oncology Centre record. The principal investigator extracts data onto a purpose-built electronic case report form with range checks, permitted-value lists and mandatory fields, in three passes (surgical, pathological and oncological), after a pilot on 15 records. A random 20% of records is extracted independently by a clinician blinded to the investigator's extraction (Cohen's kappa for categorical and intraclass correlation coefficient for continuous variables; a kappa below 0.80 for any key variable triggers re-extraction of that variable across the whole cohort). Every exposure value and every recurrence date undergoes 100% source verification by an independent second reader. Automated logic checks run before lock (operation before recurrence, recurrence before death, a bilirubin for every index CA 19-9, involved nodes not exceeding nodes examined, and no recurrence without a source-document reference); every query is logged and closed, and the dataset is locked before any inferential analysis, with the lock documented by date, file checksum and signature.

SAMPLE SIZE

The cohort is a fixed population: every eligible patient operated within the accrual window is included. Using Schoenfeld's formula with a hazard ratio of 1.8 for CA 19-9 >37 versus ≤37 U/mL, 35% of patients with a bilirubin-qualified value ≤37 U/mL, 75% cumulative recurrence, two-sided alpha 0.05 and 80% power, 100 recurrence events are required (133 patients; 153 allowing 15% attrition). A minimum of 155 analysable patients (approximately 116 events) is the threshold below which inferential analysis will not proceed; this gives 86% power for a hazard ratio of 1.8, and the smallest hazard ratio detectable with 80% power is 1.73. Institutional volume is expected to yield 170 to 190 eligible patients. The study is not powered for modest differences within individual pattern categories or for prediction-model development: power for early recurrence (odds ratio 2.30) is approximately 70%, multivariable models are capped at ten events per variable, penalised estimation is used where a pattern has fewer than 30 events, and no category with fewer than 10 events is modelled. Such findings are reported as estimates with confidence intervals and described as hypothesis-generating.

STATISTICAL ANALYSIS

Analysis populations: the principal population (all eligibility criteria met, bilirubin-qualified index CA 19-9, adjudicated recurrence status) for all primary analyses; the pattern population (adjudicated first recurrence) for the multinomial analysis; the secondary population (no bilirubin-qualified value obtainable) for sensitivity analysis S2 only; and the early-recurrence set (at least 12 months of follow-up or an event within 12 months).

Descriptive analyses: characteristics by CA 19-9 stratum with standardised mean differences rather than p-values; the distribution of the index value on raw and log2 scales with the proportion at each reporting limit; perioperative outcomes, pathology, adjuvant delivery and surveillance completeness by stratum; and follow-up duration by the reverse Kaplan-Meier method.

Primary analysis 1 (pattern): pattern-specific cumulative incidence by the Aalen-Johansen estimator with competing events (recurrence in another category; death without recurrence) at 6, 12, 24 and 36 months, compared across strata by Gray's test; Fine-Gray subdistribution hazard and cause-specific Cox models for each pattern with at least 10 events (Firth penalisation below 30 events), reported together with their interpretive difference; and multinomial logistic regression of pattern among patients who recur (reference: local/locoregional only), adjusted for the confounder set. Categories with fewer than 10 patients are collapsed in a fixed order (lung-only into other-distant-only; other-distant-only into peritoneal-only if still sparse); local/locoregional-only, liver-only and multiple-site categories are never collapsed, and any collapsing is reported.

Primary analysis 2 (timing): cumulative incidence of recurrence of any pattern with death without recurrence as the competing event, by stratum (Gray's test); primary effect estimate the subdistribution hazard ratio for >37 versus ≤37 U/mL from a multivariable Fine-Gray model adjusted for the confounder set, with a cause-specific Cox model fitted in parallel; the hazard ratio per doubling of CA 19-9 with a restricted cubic spline of adjusted hazard ratio against concentration; and restricted mean time to recurrence at 24 months by stratum.

Secondary analyses: multivariable logistic regression for early and very early recurrence in the early-recurrence set; Kaplan-Meier estimation with the log-rank test and multivariable Cox regression for recurrence-free and overall survival; descriptive post-recurrence survival by pattern and stratum; likelihood-ratio tests between nested Cox models and change in Harrell's C-index for CA 19-9 versus the pathological predictors; and the difference in time-dependent area under the curve at 12 and 24 months, with bootstrap confidence intervals, between a preoperative model (age, sex, Charlson age-comorbidity index, CT tumour size, radiological nodal status, resectability category) with and without CA 19-9.

Covariate selection is causal, not statistical. The minimal sufficient adjustment set is age, sex, Charlson age-comorbidity index, obstructive jaundice with preoperative biliary drainage, and year of surgery as a period effect. Pathological variables (pT and tumour size, pN and lymph node ratio, grade, lymphovascular and perineural invasion, margin status) are treated as mediators and are not adjusted for in the primary model; they enter a pre-specified secondary model, the comparison estimating how far the association operates through conventional pathology. Adjuvant chemotherapy receipt and regimen are modelled as a time-varying covariate to avoid immortal time bias, with a 90-day landmark analysis as a check. Postoperative complications and treatment received at recurrence are descriptive only. Stepwise selection and selection on univariable p-values are not used.

Model diagnostics and missing data: proportional hazards assessed by scaled Schoenfeld residuals, with a time-varying coefficient where violated and restricted mean survival time differences at 12 and 24 months if the exposure itself violates the assumption; influential observations by dfbeta, with re-analysis without any observation that changes the primary estimate by more than 15%; variance inflation factor threshold of 5; functional form by martingale residuals. The exposure and primary outcomes are complete in the principal population by construction. For other variables: complete-case analysis below 5% missingness (checked against the imputed result); multiple imputation by chained equations with 20 imputations between 5% and 30% (imputation model including all analysis variables, the Nelson-Aalen cumulative hazard and the event indicator; estimates combined by Rubin's rules); and no imputation above 30%, the variable being reported descriptively only. The missing-at-random assumption is discussed for each imputed variable, with a pattern-mixture sensitivity analysis where missingness is likely to depend on unobserved values.

Pre-specified sensitivity analyses (all reported, whether or not they agree with the primary analysis):

  • S1: presumed Lewis-negative non-secretors (<2 U/mL) excluded from the reference stratum.
  • S2: re-analysis of the secondary population using the CA 19-9 to bilirubin ratio, with bilirubin as a covariate.
  • S3: restriction to patients with at least 80% protocol-adherent surveillance imaging.
  • S4: interval-censored analysis, recurrence occurring between the last negative and the first positive study.
  • S5: exclusion of recurrences detected by symptom-triggered rather than protocol-driven imaging.
  • S6: 90-day landmark analysis for adjuvant chemotherapy in place of the time-varying covariate.
  • S7: multiple imputation for assay values reported beyond the limits of quantification.
  • S8: primary contrast repeated at published alternative thresholds of 100, 200 and 500 U/mL.
  • S9: operating surgeon added as a shared frailty term.
  • S10: exclusion of patients operated in 2017 and 2018 (learning-curve and period effects).

Subgroups, multiplicity and model performance: five pre-specified exploratory subgroups (margin status R0 versus R1; nodal status N0 versus N1/N2; receipt of adjuvant chemotherapy; obstructive jaundice at presentation; grade, well or moderately versus poorly differentiated) are examined by interaction terms and shown in a forest plot. No alpha adjustment is applied between the two primary objectives, which address distinct outcomes; the Benjamini-Hochberg procedure controls the false discovery rate at 5% within the family of pattern-specific hazard models, with unadjusted and adjusted p-values reported; secondary, subgroup, sensitivity and exploratory analyses are not alpha-adjusted and are labelled hypothesis-generating. Discrimination is quantified by Harrell's C-index and time-dependent area under the curve at 12 and 24 months, calibration by predicted versus observed cumulative incidence in deciles of predicted risk, and optimism by bootstrap resampling with 1000 replicates repeating the whole modelling procedure; performance is described as apparent, internally validated performance in a single-centre cohort, with no claim of external validity. Analyses use R version 4.4 or later (survival, cmprsk, riskRegression, prodlim, mstate, rms, mice, maxstat, nnet, timeROC, coxphf, ggplot2) with version-controlled code.

BIAS AND LIMITATIONS

Pre-specified mitigation: selection bias from excluding patients without a bilirubin-qualified value (excluded patients characterised; S2); detection bias from more intensive surveillance of patients with an elevated marker (surveillance completeness reported by stratum; S3 to S5); incorporation bias (imaging or histological confirmation of every event; adjudicators blinded to all marker values); information bias (structured case report form, 20% duplicate extraction, 100% source verification of exposure and primary outcomes, standardised external definitions); immortal time bias (time-varying adjuvant chemotherapy; S6); competing-risk misestimation (Aalen-Johansen and Fine-Gray methods, Kaplan-Meier reserved for composite endpoints); confounding by indication (biliary drainage in the adjustment set); assay drift (platform recorded per year; year of surgery adjusted for); attrition (structured tracing; loss reported by stratum); and overfitting (events-per-variable cap, penalisation, bootstrap optimism correction). Limitations: retrospective single-centre design (association and temporal sequence, not causation; unmeasured confounding such as molecular subtype and circulating tumour DNA status); interval-scheduled imaging, so times to recurrence are upper bounds; lower sensitivity of CT for peritoneal recurrence; non-secretor status inferred rather than genotyped; heterogeneous adjuvant regimens; and limited power for pattern-specific inference.

ETHICS, CONSENT AND DATA PROTECTION

Approved by the Medical Research Ethics Committee / Institutional Review Board, Faculty of Medicine, Minia University (MUFMIRB approval number 2216:10/26, 3 October 2026). The study is conducted in accordance with the Declaration of Helsinki (2013 revision) and Egyptian Clinical Medical Research Law No. 214 of 2020 and its Executive Regulation No. 927 of 2022; no investigational product or device is involved. Individual informed consent is waived because the research involves no more than minimal risk, the waiver does not adversely affect participants' rights or welfare, the research could not practicably be carried out otherwise (a substantial proportion of the cohort is deceased, and requiring consent would introduce severe non-random selection bias among those with the outcome of interest), and a study summary is available to the department and to any surviving patient or family member who enquires. Where a surviving patient or next of kin is telephoned solely to establish vital status, verbal permission is sought at the start of the call and nothing is requested beyond vital status and the fact and date of any recurrence. Each patient receives a sequential study identifier; the analysis dataset contains no name, hospital number, national identification number, address or telephone number. The linkage file is encrypted, accessible only to the principal investigator and destroyed 5 years after publication; data are held on encrypted institutional storage, never on personal devices, personal cloud accounts or removable media; access is logged; and records are retained for 10 years from publication. No individual-level data leave Minia University, no specimens are transferred, and no data are shared with any commercial entity. Access to Minia Oncology Centre records is subject to that centre's institutional permission.

ORGANISATION, FUNDING AND DISSEMINATION

Single-investigator study: the principal investigator holds every study role and is the guarantor of the data and analysis. Four functions are delegated to clinicians independent of the study (two blinded outcome assessors, a blinded adjudicator, and an independent second reader for duplicate extraction and source verification), who take no part in design, analysis, interpretation or reporting. The study is unfunded and uses existing institutional records; the investigator has no financial or non-financial interest in the CA 19-9 assay, any assay manufacturer or any therapy referenced. Results will be submitted for peer-reviewed publication irrespective of their direction, reported according to STROBE, and added to this record within 12 months of database lock. Substantive amendments (eligibility, exposure or primary outcome definitions, primary analysis) will be approved by the ethics committee before implementation and recorded here.

研究の種類

観察的

入学 (推定)

180

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Minya Governorate
      • Minya、Minya Governorate、エジプト、61519
        • Minia university oncology hospital
        • コンタクト:
      • Minya、Minya Governorate、エジプト
        • Liver and GIT Hospital, Faculty of Medicine, Minia University
        • コンタクト:
        • 主任研究者:
          • Saleh Khairy Saleh, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Consecutive adults (18 years or older) who underwent curative-intent pancreatoduodenectomy for histologically confirmed pancreatic ductal adenocarcinoma of the pancreatic head or uncinate process at the Hepatopancreatobiliary and Surgical Oncology Unit, Liver and GIT Hospital, Faculty of Medicine, Minia University, Egypt, between 1 January 2017 and 31 December 2024, with adjuvant treatment and surveillance records held at Minia Oncology Centre. Every pancreatoduodenectomy in the accrual window is screened from the operative logbook, cross-checked against the theatre register and the pathology accession database, with no sampling fraction.

説明

Inclusion Criteria:

  • Age 18 years or older at operation.
  • Pancreatoduodenectomy (classical Whipple or pylorus-preserving; open or minimally invasive) with curative intent between 1 January 2017 and 31 December 2024 at the Liver and GIT Hospital, Minia University.
  • Histologically confirmed pancreatic ductal adenocarcinoma, including accepted morphological variants, of the pancreatic head or uncinate process.
  • Macroscopically complete resection (R0 or R1; R1 defined as tumour within 1 mm of a resection margin).
  • Index preoperative serum CA 19-9 available: measured within 30 days before operation with a total bilirubin ≤2 mg/dL drawn within 72 hours of the CA 19-9 sample (the post-drainage value where preoperative biliary drainage was performed).
  • Follow-up of at least 6 months, or documented recurrence or death at any earlier point.

Exclusion Criteria:

  • Histology other than pancreatic ductal adenocarcinoma: ampullary carcinoma, distal cholangiocarcinoma, duodenal carcinoma, neuroendocrine neoplasm, acinar cell carcinoma, solid pseudopapillary neoplasm, non-invasive intraductal papillary mucinous neoplasm, or metastasis from another primary.
  • Body or tail tumour requiring distal pancreatectomy, or total pancreatectomy performed.
  • R2 resection, aborted resection, or M1 disease at operation, including histologically confirmed para-aortic (station 16) nodal metastasis at resection.
  • Neoadjuvant chemotherapy or chemoradiotherapy (such patients are described in a supplementary table only and never pooled with the principal cohort).
  • No preoperative CA 19-9 within 30 days, or none obtainable at a total bilirubin ≤2 mg/dL (these patients form the secondary cohort, used only in sensitivity analysis S2).
  • Death within 90 days of operation without documented recurrence (reported separately as postoperative mortality).
  • Synchronous second malignancy under treatment, or prior malignancy treated within 5 years, other than adequately treated non-melanoma skin cancer or in-situ cervical carcinoma.
  • Records irretrievable, or too incomplete to determine the exposure or the primary outcome.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:RETROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
Normal preoperative CA 19-9 (≤37 U/mL)

Adults who underwent curative-intent pancreatoduodenectomy for pancreatic ductal adenocarcinoma of the head or uncinate process between 1 January 2017 and 31 December 2024 whose index preoperative serum CA 19-9 was ≤37 U/mL. The index value is the last CA 19-9 within 30 days before surgery drawn within 72 hours of a total bilirubin ≤2 mg/dL and, after preoperative biliary drainage, the post-drainage value. Includes presumed Lewis-negative non-secretors (<2 U/mL) and normal levels (2-37 U/mL), also reported as separate ordinal strata; non-secretors are removed from this group in sensitivity analysis S1. Reference group for the primary contrast. Surgery and CA 19-9 testing were delivered as routine care; nothing is assigned or changed by the study.

Curative-intent pancreatoduodenectomy (classical Whipple or pylorus-preserving; open or minimally invasive) with standard ISGPS lymphadenectomy, with mesopancreatic excision, an artery-first approach and venous resection where indicated, performed as routine care at the Liver and GIT Hospital, Minia University, between 1 January 2017 and 31 December 2024. Specimens were reported synoptically against the AJCC eighth edition dataset, applying the 1 mm margin rule. The operation is not assigned, scheduled or modified by the study; operative and pathology data are extracted retrospectively from existing records.

他の名前:
  • ホイップル手順
  • Pylorus-preserving pancreatoduodenectomy

Exposure of interest. Serum CA 19-9 measured during routine preoperative care by electrochemiluminescence immunoassay and retrieved from laboratory records; no sample is taken for the study. Index value: the last CA 19-9 within 30 days before operation with a contemporaneous total bilirubin ≤2 mg/dL (≤34 µmol/L) drawn within 72 hours of the CA 19-9 sample; after preoperative biliary drainage, the post-drainage value meeting this criterion (pre-drainage values are recorded but never used). Where several values qualify, the one closest to surgery is used. Analysed as binary (>37 vs ≤37 U/mL; primary contrast), ordinal (<2, 2-37, >37-200, >200 U/mL) and continuous (log2[CA 19-9 + 1]) variables.

他の名前:
  • Carbohydrate antigen 19-9
  • Cancer antigen 19-9
  • Sialyl Lewis a
Elevated preoperative CA 19-9 (>37 U/mL)

Adults who underwent curative-intent pancreatoduodenectomy for pancreatic ductal adenocarcinoma of the head or uncinate process between 1 January 2017 and 31 December 2024 whose index preoperative serum CA 19-9 (same bilirubin-qualified definition) was >37 U/mL. Subdivided for descriptive and trend analyses into moderately elevated (>37-200 U/mL) and markedly elevated (>200 U/mL) strata. Exposed group for the primary contrast. Surgery and CA 19-9 testing were delivered as routine care; nothing is assigned or changed by the study.

Curative-intent pancreatoduodenectomy (classical Whipple or pylorus-preserving; open or minimally invasive) with standard ISGPS lymphadenectomy, with mesopancreatic excision, an artery-first approach and venous resection where indicated, performed as routine care at the Liver and GIT Hospital, Minia University, between 1 January 2017 and 31 December 2024. Specimens were reported synoptically against the AJCC eighth edition dataset, applying the 1 mm margin rule. The operation is not assigned, scheduled or modified by the study; operative and pathology data are extracted retrospectively from existing records.

他の名前:
  • ホイップル手順
  • Pylorus-preserving pancreatoduodenectomy

Exposure of interest. Serum CA 19-9 measured during routine preoperative care by electrochemiluminescence immunoassay and retrieved from laboratory records; no sample is taken for the study. Index value: the last CA 19-9 within 30 days before operation with a contemporaneous total bilirubin ≤2 mg/dL (≤34 µmol/L) drawn within 72 hours of the CA 19-9 sample; after preoperative biliary drainage, the post-drainage value meeting this criterion (pre-drainage values are recorded but never used). Where several values qualify, the one closest to surgery is used. Analysed as binary (>37 vs ≤37 U/mL; primary contrast), ordinal (<2, 2-37, >37-200, >200 U/mL) and continuous (log2[CA 19-9 + 1]) variables.

他の名前:
  • Carbohydrate antigen 19-9
  • Cancer antigen 19-9
  • Sialyl Lewis a

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Anatomical pattern of first recurrence, by index preoperative CA 19-9 group (>37 vs ≤37 U/mL)
時間枠:From pancreatoduodenectomy (1 January 2017 to 31 December 2024) to first recurrence; cumulative incidence at 6, 12, 24 and 36 months; up to 116 months (follow-up censored 31 August 2026)

First recurrence classified as local/locoregional only, liver only, peritoneal only, lung or other distant only (including para-aortic station 16 nodes), or multiple synchronous sites (two or more categories within 30 days) by two independent clinicians blinded to all CA 19-9 values, with a third blinded adjudicator for disagreement. Recurrence requires radiological or histological confirmation; a rising CA 19-9 alone never counts. Reported as number (%) of patients in each category and as pattern-specific cumulative incidence (Aalen-Johansen; competing events: recurrence at another site and death without recurrence) compared between groups by Gray's test, with Fine-Gray subdistribution and cause-specific hazard ratios for each pattern with ≥10 events and multinomial odds ratios among patients who recur (reference: local/locoregional only).

From pancreatoduodenectomy (1 January 2017 to 31 December 2024) to first recurrence; cumulative incidence at 6, 12, 24 and 36 months; up to 116 months (follow-up censored 31 August 2026)
Time to first recurrence, with death without recurrence as a competing event, by index preoperative CA 19-9 group
時間枠:From pancreatoduodenectomy to first confirmed recurrence, death or last follow-up; cumulative incidence at 6, 12, 24 and 36 months; up to 116 months (follow-up censored 31 August 2026)

Months from operation to the first imaging study or biopsy confirming recurrence (date of the confirmatory study when established by interval progression); death without recurrence is a competing event; patients alive and recurrence-free are censored at last documented contact. Primary effect estimate: subdistribution hazard ratio (Fine-Gray) for CA 19-9 >37 vs ≤37 U/mL, adjusted for age, sex, Charlson age-comorbidity index, obstructive jaundice with preoperative biliary drainage, and year of surgery, with a cause-specific Cox model in parallel. Also reported: cumulative incidence of recurrence by group (Gray's test), hazard ratio per doubling of CA 19-9 (log2 scale) with a restricted cubic spline, and restricted mean time to recurrence at 24 months.

From pancreatoduodenectomy to first confirmed recurrence, death or last follow-up; cumulative incidence at 6, 12, 24 and 36 months; up to 116 months (follow-up censored 31 August 2026)

二次結果の測定

結果測定
メジャーの説明
時間枠
Early recurrence (within 12 months of surgery)
時間枠:12 months after pancreatoduodenectomy

Number (%) of patients with a confirmed first recurrence at or before 12 months after operation, by CA 19-9 group, in the early-recurrence set (patients with at least 12 months of follow-up or an event within 12 months; the number excluded is reported). Association expressed as an adjusted odds ratio with 95% CI from multivariable logistic regression using the primary adjustment set.

12 months after pancreatoduodenectomy
Very early recurrence (within 6 months of surgery)
時間枠:6 months after pancreatoduodenectomy

Number (%) of patients with a confirmed first recurrence at or before 6 months after operation, by CA 19-9 group, in the early-recurrence set. Association expressed as an adjusted odds ratio with 95% CI from multivariable logistic regression using the primary adjustment set.

6 months after pancreatoduodenectomy
Site-specific cumulative incidence of first recurrence
時間枠:6, 12, 24 and 36 months after pancreatoduodenectomy

Cumulative incidence (%, 95% CI) of local/locoregional, hepatic, peritoneal, pulmonary and other distant first recurrence, estimated by the Aalen-Johansen method with competing events, overall and across the four ordinal CA 19-9 strata (<2, 2-37, >37-200 and >200 U/mL), with Gray's test and a test for trend across the three producing strata.

6, 12, 24 and 36 months after pancreatoduodenectomy
Recurrence-free survival
時間枠:From pancreatoduodenectomy to recurrence, death or last follow-up; up to 116 months (follow-up censored 31 August 2026)

Time from operation to confirmed recurrence or death from any cause, by CA 19-9 group: Kaplan-Meier estimates (median and probabilities at 12, 24 and 36 months) compared by the log-rank test, and adjusted hazard ratio with 95% CI from multivariable Cox regression.

From pancreatoduodenectomy to recurrence, death or last follow-up; up to 116 months (follow-up censored 31 August 2026)
Overall survival
時間枠:From pancreatoduodenectomy to death or last follow-up; up to 116 months (follow-up censored 31 August 2026)

Time from operation to death from any cause, by CA 19-9 group, with vital status from hospital and Minia Oncology Centre records and, where approved, a single telephone enquiry: Kaplan-Meier estimates (median and probabilities at 12, 24 and 36 months) compared by the log-rank test, and adjusted hazard ratio with 95% CI from multivariable Cox regression.

From pancreatoduodenectomy to death or last follow-up; up to 116 months (follow-up censored 31 August 2026)
Post-recurrence survival
時間枠:From first confirmed recurrence to death or last follow-up; up to 116 months (follow-up censored 31 August 2026)

Time from first confirmed recurrence to death from any cause among patients who recur, by recurrence pattern and by CA 19-9 group (Kaplan-Meier median with 95% CI). Presented descriptively because it conditions on a post-baseline event.

From first confirmed recurrence to death or last follow-up; up to 116 months (follow-up censored 31 August 2026)
Incremental prognostic discrimination of preoperative CA 19-9 for recurrence
時間枠:12 and 24 months after pancreatoduodenectomy

Difference in time-dependent area under the ROC curve (bootstrap 95% CI) between a preoperative model of age, sex, Charlson age-comorbidity index, CT tumour size, radiological nodal status and resectability category, and the same model plus CA 19-9; with the change in Harrell's C-index. Reported as apparent and bootstrap optimism-corrected (1000 replicates) internal performance; no external validity is claimed.

12 and 24 months after pancreatoduodenectomy
Prognostic contribution of CA 19-9 relative to established pathological predictors
時間枠:From pancreatoduodenectomy to recurrence, death or last follow-up; up to 116 months (follow-up censored 31 August 2026)

Likelihood-ratio tests between nested Cox models and change in Harrell's C-index for CA 19-9 versus pathological predictors (pT and tumour size, pN and lymph node ratio, grade, lymphovascular and perineural invasion, margin status), and comparison of the primary and pathology (mediator)-adjusted models to estimate how far the CA 19-9 association operates through conventional pathology.

From pancreatoduodenectomy to recurrence, death or last follow-up; up to 116 months (follow-up censored 31 August 2026)
Isolated local recurrence and salvage treatment
時間枠:From pancreatoduodenectomy to 3 months after first recurrence; up to 116 months (follow-up censored 31 August 2026)

Number (%) of patients whose first recurrence is local/locoregional only with no distant disease over the following 3 months, by CA 19-9 group, with any salvage treatment received recorded descriptively.

From pancreatoduodenectomy to 3 months after first recurrence; up to 116 months (follow-up censored 31 August 2026)

その他の成果指標

結果測定
メジャーの説明
時間枠
Postoperative complications
時間枠:From pancreatoduodenectomy to 90 days after surgery

Clavien-Dindo grade, comprehensive complication index (0-100), ISGPS-defined postoperative pancreatic fistula (biochemical leak, grade B, grade C), delayed gastric emptying and post-pancreatectomy haemorrhage, ISGLS bile leak, ISGPS chyle leak, and length of hospital stay, by CA 19-9 group. Descriptive context for the primary analyses; not adjusted for in outcome models.

From pancreatoduodenectomy to 90 days after surgery
Adjuvant chemotherapy delivery
時間枠:From pancreatoduodenectomy to the end of adjuvant treatment, up to 12 months after surgery

Number (%) of patients starting adjuvant chemotherapy, regimen (gemcitabine monotherapy, gemcitabine with capecitabine, modified FOLFIRINOX, other) and interval from operation to the first cycle, by CA 19-9 group.

From pancreatoduodenectomy to the end of adjuvant treatment, up to 12 months after surgery
Surveillance completeness and detection pathway
時間枠:From pancreatoduodenectomy to recurrence, death or last follow-up; up to 116 months (follow-up censored 31 August 2026)

Proportion of protocol-scheduled surveillance imaging studies performed (CT of chest, abdomen and pelvis every 3 months for 2 years, then every 6 months to 5 years) and proportion of recurrences first detected on symptom-triggered rather than scheduled imaging, by CA 19-9 group; used to assess detection bias (sensitivity analyses S3 and S5).

From pancreatoduodenectomy to recurrence, death or last follow-up; up to 116 months (follow-up censored 31 August 2026)
Exploratory data-driven CA 19-9 threshold for early recurrence
時間枠:12 months after pancreatoduodenectomy

CA 19-9 cut-point best separating early (≤12 months) from late recurrence, identified by maximally selected rank statistics with the Hothorn-Lausen exact correction for multiple cut-point testing and compared with published thresholds. Exploratory; labelled as requiring external validation and not presented as a validated cut-off.

12 months after pancreatoduodenectomy
Characteristics and outcomes of patients with CA 19-9 <2 U/mL (presumed Lewis-negative non-secretors)
時間枠:From pancreatoduodenectomy to recurrence, death or last follow-up; up to 116 months (follow-up censored 31 August 2026)

Baseline characteristics, pattern of first recurrence, time to recurrence and overall survival of patients with an index CA 19-9 below 2 U/mL at total bilirubin ≤2 mg/dL, described separately and compared with patients with 2-37 U/mL. Non-secretor status is inferred from the value, not genotyped.

From pancreatoduodenectomy to recurrence, death or last follow-up; up to 116 months (follow-up censored 31 August 2026)
Prognostic value of the CA 19-9 to total bilirubin ratio in patients without a bilirubin-qualified CA 19-9
時間枠:From pancreatoduodenectomy to recurrence, death or last follow-up; up to 116 months (follow-up censored 31 August 2026)

In the secondary cohort (patients meeting every criterion except a CA 19-9 measured at total bilirubin ≤2 mg/dL), subdistribution hazard ratio for time to recurrence per unit of the CA 19-9 to bilirubin ratio, with bilirubin as a covariate (sensitivity analysis S2). These patients are characterised against the principal cohort and never pooled with it.

From pancreatoduodenectomy to recurrence, death or last follow-up; up to 116 months (follow-up censored 31 August 2026)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Saleh Khairy Saleh, MD、Minia University

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月1日

一次修了 (推定)

2027年4月30日

研究の完了 (推定)

2027年4月30日

試験登録日

最初に提出

2026年11月13日

QC基準を満たした最初の提出物

2026年11月13日

最初の投稿 (実際)

2026年11月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月13日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

De-identified individual participant data underlying the published results (the locked analysis dataset with its data dictionary) and the R analysis code will be shared with qualified investigators on reasonable written request, subject to approval by the Minia University Faculty of Medicine Research Ethics Committee and a data-sharing agreement prohibiting re-identification and onward transfer. Direct identifiers (name, hospital number, national identification number, address, telephone number) are never released. No individual-level data will be deposited in an open repository, because the combination of dates, rare pathological features and a single-institution setting carries a residual re-identification risk that an open deposit could not mitigate.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する